UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning Balance, Shares at Jun. 30, 2017		7,880,347
Beginning Balance, Amount at Jun. 30, 2017		$ 7,880	$ 23,269,861	$ (27,530,721)	$ (4,252,980)
Proceeds from issuance of common stock and warrants, Shares		64,000
Proceeds from issuance of common stock and warrants, Amount		$ 64	79,936		80,000
Shares issued for services, Shares		175,000
Shares issued for services, Amount		$ 175	34,825		35,000
Shares issued for financing, Shares		200,000
Shares issued for financing, Amount		$ 200	29,800		30,000
Stock-based compensation, Amount			15,925		15,925
Net loss				(431,483)	(431,483)
Ending Balance, Shares at Sep. 30, 2017		8,319,347
Ending Balance, Amount at Sep. 30, 2017		$ 8,319	23,430,347	(27,962,204)	(4,523,538)
Beginning Balance, Shares at Jun. 30, 2017		7,880,347
Beginning Balance, Amount at Jun. 30, 2017		$ 7,880	23,269,861	(27,530,721)	(4,252,980)
Net loss					(4,499,065)
Ending Balance, Shares at Mar. 31, 2018		9,039,347
Ending Balance, Amount at Mar. 31, 2018		$ 9,039	26,826,015	(32,029,786)	(5,194,732)
Beginning Balance, Shares at Sep. 30, 2017		8,319,347
Beginning Balance, Amount at Sep. 30, 2017		$ 8,319	23,430,347	(27,962,204)	(4,523,538)
Proceeds from issuance of common stock and warrants, Shares		80,000
Proceeds from issuance of common stock and warrants, Amount		$ 80	99,920		100,000
Stock-based compensation, Amount			15,925		15,925
Loss from extinguishment associated with debt discounts and finance costs			3,072,134		3,072,134
Net loss				(3,412,980)	(3,412,980)
Ending Balance, Shares at Dec. 31, 2017		8,399,347
Ending Balance, Amount at Dec. 31, 2017		$ 8,399	26,618,326	(31,375,184)	(4,748,459)
Proceeds from issuance of common stock and warrants, Shares		220,000
Proceeds from issuance of common stock and warrants, Amount		$ 220	109,780		110,000
Shares issued for services, Shares		100,000
Shares issued for services, Amount		$ 100	14,900		15,000
Shares issued for financing, Amount					0
Stock-based compensation, Shares		320,000
Stock-based compensation, Amount		$ 320	83,009		83,329
Loss from extinguishment associated with debt discounts and finance costs					0
Net loss				(654,602)	(654,602)
Ending Balance, Shares at Mar. 31, 2018		9,039,347
Ending Balance, Amount at Mar. 31, 2018		$ 9,039	26,826,015	(32,029,786)	(5,194,732)
Beginning Balance, Shares at Jun. 30, 2018		9,039,347
Beginning Balance, Amount at Jun. 30, 2018		$ 9,039	26,856,647	(32,449,513)	(5,583,827)
Stock-based compensation, Amount			29,199		29,199
Conversion of short term convertible notes payable (principal), Shares		799,318
Conversion of short term convertible notes payable (principal), Amount		$ 799	15,290		16,089
Conversion of short term convertible notes payable (Interest), Shares		58,446
Conversion of short term convertible notes payable (Interest), Amount		$ 59	2,660		2,719
Conversion of financing fees related to conversion of short term convertible notes payable, Shares		212,236
Conversion of financing fees related to conversion of short term convertible notes payable, Amount		$ 212	3,271		3,483
Net loss				(537,299)	(537,299)
Ending Balance, Shares at Sep. 30, 2018		10,109,347
Ending Balance, Amount at Sep. 30, 2018		$ 10,109	26,907,067	(32,986,812)	(6,069,636)
Beginning Balance, Shares at Jun. 30, 2018		9,039,347
Beginning Balance, Amount at Jun. 30, 2018		$ 9,039	26,856,647	(32,449,513)	(5,583,827)
Net loss					(1,298,646)
Ending Balance, Shares at Mar. 31, 2019	51	80,073,096
Ending Balance, Amount at Mar. 31, 2019	$ 1	$ 80,073	27,003,833	(33,748,159)	(6,664,252)
Beginning Balance, Shares at Sep. 30, 2018		10,109,347
Beginning Balance, Amount at Sep. 30, 2018		$ 10,109	26,907,067	(32,986,812)	(6,069,636)
Stock-based compensation, Amount			22,494		22,494
Conversion of short term convertible notes payable (principal), Shares		6,085,795
Conversion of short term convertible notes payable (principal), Amount		$ 6,084	15,738		21,822
Conversion of short term convertible notes payable (Interest), Shares		1,749,212
Conversion of short term convertible notes payable (Interest), Amount		$ 1,749	4,756		6,505
Conversion of financing fees related to conversion of short term convertible notes payable, Shares		3,896,442
Conversion of financing fees related to conversion of short term convertible notes payable, Amount		$ 3,897	6,598		10,495
Recognize cost associated with beneficial conversion feature			87,000		87,000
Net loss				(371,138)	(371,138)
Ending Balance, Shares at Dec. 31, 2018		21,840,796
Ending Balance, Amount at Dec. 31, 2018		$ 21,839	27,043,653	(33,357,950)	(6,292,458)
Stock-based compensation, Amount			22,494		22,494
Conversion of short term convertible notes payable (principal), Shares		38,483,531
Conversion of short term convertible notes payable (principal), Amount		$ 38,487	7,389		45,876
Conversion of short term convertible notes payable (Interest), Shares		5,854,094
Conversion of short term convertible notes payable (Interest), Amount		$ 5,855	1,802		7,657
Conversion of financing fees related to conversion of short term convertible notes payable, Shares		13,894,675
Conversion of financing fees related to conversion of short term convertible notes payable, Amount		$ 13,892	880		14,772
Preferred issued to executive employees, Shares	51
Preferred issued to executive employees, Amount	$ 1		14,999		14,999
Reclass insufficient authorized shares to derivative liability			(87,384)		(87,384)
Net loss				(390,209)	(390,209)
Ending Balance, Shares at Mar. 31, 2019	51	80,073,096
Ending Balance, Amount at Mar. 31, 2019	$ 1	$ 80,073	$ 27,003,833	$ (33,748,159)	$ (6,664,252)

CEREBAIN BIOTECH CORP. 10-Q